Add to ORKGThe paper present overview of the etiology and diagnostic evaluation and treatment of atrophic vaginitis. The author presented also the symptoms and diagnostic elements. The authors stresses the diff erences in treatment of atrophic vaginitis in women with breast cancer. In detail nonhormonal and hormonal treatment of atrophic vaginitis were discussed. The article drew attention to new therapies with intravaginal dehydroepiandrosterone administration and estrogens agonists.W pracy przedstawiono etiologię zanikowego zapalenia pochwy (ZZP), dolegliwości podmiotowe i przedmiotowe, diagnostykę i leczenie. Zwrócono uwagę na odrębności leczenia choroby u chorych z rakiem sutka. Omówiono leczenie niehormonalne i miejscowe leczenie estrogenami, deh...
Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus a...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatmen...
The aim of this study was to evaluate the effectiveness of low molecular weight hyaluronic acid oral...
Management of breast cancer includes systematic therapies including chemotherapy and endocrine thera...
Background: Due to the defficiency of sex hormone estrogen after the menopause, the quality of woman...
Abstract: Management of breast cancer includes systematic therapies including chemotherapy and endoc...
This article discusses the problems of rational pharmacotherapy in women with vulvovaginal atrophy d...
The objective: to evaluate the clinical effectiveness of treatment of atrophic vaginitis in menopaus...
The problem of atrophic vaginitis (AV) in postmenopause is widespread; it is considered a natural ag...
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical ...
Vaginal atrophy symptoms such as dryness, irritation, and itching, are common after menopause. Vagin...
Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%-60% of postmenopausal women w...
Among gynaecological diseases in women of reproductive age the leading place is occupied by inflamma...
A review of the literature on the causes of vaginitis, vaginal microflora in women with various path...
AbstractIntroductionVaginal atrophy, which may affect up to 45% of postmenopausal women, is often as...
Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus a...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatmen...
The aim of this study was to evaluate the effectiveness of low molecular weight hyaluronic acid oral...
Management of breast cancer includes systematic therapies including chemotherapy and endocrine thera...
Background: Due to the defficiency of sex hormone estrogen after the menopause, the quality of woman...
Abstract: Management of breast cancer includes systematic therapies including chemotherapy and endoc...
This article discusses the problems of rational pharmacotherapy in women with vulvovaginal atrophy d...
The objective: to evaluate the clinical effectiveness of treatment of atrophic vaginitis in menopaus...
The problem of atrophic vaginitis (AV) in postmenopause is widespread; it is considered a natural ag...
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical ...
Vaginal atrophy symptoms such as dryness, irritation, and itching, are common after menopause. Vagin...
Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%-60% of postmenopausal women w...
Among gynaecological diseases in women of reproductive age the leading place is occupied by inflamma...
A review of the literature on the causes of vaginitis, vaginal microflora in women with various path...
AbstractIntroductionVaginal atrophy, which may affect up to 45% of postmenopausal women, is often as...
Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus a...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatmen...
The aim of this study was to evaluate the effectiveness of low molecular weight hyaluronic acid oral...
